title: 340B program presents opportunities--and challenges.
abstract: The 340B program provides an opportunity for hospitals to achieve significant cost savings on outpatient drugs. Disputes surrounding the Medicare DSH payment calculation, and potential misunderstandings of Medicare provider-based rules, pose obstacles to hospitals that wish to continue or gain participation in the program. Eligible hospitals should pay close attention not only to the rules governing the 340B program, but also to Medicare reimbursement rules to ensure access to drug discounts available under the program.
authors.affiliation: King & Spalding, Washington, DC, USA. ckeough@kslaw.com
authors.forename: Christopher L
authors.initials: CL
authors.lastname: Keough
authors.forename: Stephanie A
authors.initials: SA
authors.lastname: Webster
mesh_terms: D000553:Ambulatory Care; D017046:Cost Savings; D016527:Drug Costs / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D004469:Economics, Hospital; D004364:Pharmaceutical Preparations / Q000191:economics*; D014481:United States; D014492:United States Public Health Service / Q000331:legislation & jurisprudence
chemical_list: D004364:Pharmaceutical Preparations